Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

Stock Information for Outlook Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Outlook Therapeutics Inc.

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
Kaskela Law LLC Announces Shareholder Investigation of Outlook Therapeutics, Inc. (OTLK) and Encourages Investors to Contact the Firm
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.